# BioTheryX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biotheryx

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.biotheryx.com
- Total disclosed funding: $127M
- Latest round: Series E (May 20, 2021)
- Investors on record: 13

## About

Based in New York, US and founded in 2008, BioTheryX Inc. is a developer of anti-cancer drugs to treat a broad range of therapeutic areas including oncology, inflammation, and other diseases. As of August 2021, David Stirling is the president and CEO of the company. The company has been able to raise USD 128.65 million from five funding rounds. Its latest funding was raised on May 2021 from a Series E round led by Farallon Capital Management and other investors including Avidity Partners, Deep Track Capital, Irving Investors, Lumira Ventures, Point72, and Rock Springs Capital. 

The company offers multiple products, including BTX-2640 for Inflammation and Oncology, BTX-1188 for AML and MDS, BTX-1050 for Immune Modulation, Oncology, BTX-A51 for AML, MDS, Solid Tumors, PHMs for Autoimmune Diseases and Immuno-Oncology, and BTX-2541 for Cancers. Also, the company provides technology platform centers, including PHMs, PHM-PTCs, and Multi-Kinase Inhibitor P53 protein modulation focusing on degrading proteins to create life-saving medicines. The Protein Homeostatic Modulators (PHM) technology of the company utilizes a protein disposal system of the body to remove and degrade disease-causing proteins.

The company plans to use the proceeds from its March 2021 funding round to advance multiple molecular glues, PHM-based PROTACs and monovalent degraders, including BTX-1188, toward clinical development. Also, the company plans to reach milestones in Phase 1 lead multi-kinase inhibitor BTX-A51and IND-enabling molecular glue program BTX-1188 by the end of 2021.

## Funding rounds

- Series E, May 20, 2021, $92M — Alexandria Venture Investments, Tekla Capital Management, Wedbush Securities Inc., Rock Springs Capital, Farallon Capital Management, Point72, Janus Henderson Investors, Surveyor Capital, Irving Investors, Avidity Partners, Deep Track Capital, Lumira Ventures
- Series D, Jul 28, 2020, $35M — BDT & MSD Partners

## Investors

- BDT & MSD Partners (https://capitalatlas.ai/funds/bdt-msd-partners) — Series D
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series E
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series E
- Wedbush Securities Inc. — Series E
- Rock Springs Capital — Series E
- Farallon Capital Management (https://capitalatlas.ai/funds/farallon-capital-management) — Series E
- Point72 (https://capitalatlas.ai/funds/point72) — Series E
- Janus Henderson Investors — Series E
- Surveyor Capital — Series E
- Irving Investors (https://capitalatlas.ai/funds/irving-investors) — Series E
- Avidity Partners — Series E
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series E
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series E